There is no limit to the number of prior lines of treatment a patient has received There is no limit to the number of prior lines of treatment a patient has received H&N, NETs, biliary tract, CUP: one or two prior chemotherapy-containing lines Diagnosis of platinum resistant or refractory OVCA having received or fewer prior lines, or recurrent advanced NSCLC having received or fewer prior lines For Arm B: must have received at least but not more than prior lines of therapy. CRC - No more than four different prior lines of systemic therapy for advanced disease Cohort : Are BRCA negative and have received or more prior lines of therapy. Cohort : Are BRCA negative and have received less than prior lines of therapy. Have received no more than prior lines of therapy (maintenance therapy given in the metastatic setting will not be considered a separate regimen). Generally, treatments that are separated by an event of progression are considered different regimens. Has previously received at least lines of myeloma therapy. Must have had at least two () prior lines of systemic therapy for liposarcoma (not to exceed prior lines) There is no limitation on the number of prior lines of systemic therapy More than lines of previous cytotoxic therapies. For patients of CTCL who failed romidepsin, more than lines of previous therapies No more than prior lines of treatment for cGVHD. The patient has received to prior lines of therapy; by definition, a single line of therapy may consist of or more agents, and may include induction, hematopoietic stem cell transplantation, and maintenance therapy; radiotherapy, bisphosphonate, or a single short course of steroids (i.e., less than or equal to the equivalent of dexamethasone mg/day for days) would not be considered prior lines of therapy to prior lines of therapy No more than two prior lines of cytotoxic-containing chemotherapy regimens for advanced disease. There is no limit for prior targeted therapy, hormonal therapy and immunotherapy (such as nivolumab). PHASE IB: =< lines of prior systemic therapy for patients with progressive locally-advanced disease Patients may have had no more than prior lines of systemic therapy; prior therapy with a MET inhibitor is allowed as long as the patient has not had progressive disease while receiving the agent Phase II: histologically confirmed colorectal adenocarcinoma post at least two lines of therapy, NSCLC post at least two lines of therapy, or granulosa cell ovarian cancer post at least one line of therapy; patients must have measurable disease Has received four or more systemic anticancer regimens for mCRPC. Treatment with docetaxel or abiraterone for non-castrate metastatic disease is permissible and does not count towards the lines of therapy for mCRPC. A line is a regimen. Combinations of hormones and other types of therapies count as single lines One to four prior lines of therapy Greater than lines of prior systemic therapy for CRPC ARM I INCLUSION CRITERIA: There are no restrictions on the number of prior lines of treatment for systemic disease Patients must have had at least prior lines of therapy More than lines of prior systemic therapy in the preceding three years Patients must have had at least two, but not more than four prior lines of therapy for their disease, with lines of therapy being separated by the presence of documented disease progression; using this definition, treatment with induction therapy, followed by high dose chemotherapy and autologous stem cell transplantation, and finally by maintenance therapy, would constitute one line, provided that multiple myeloma did not meet criteria for progression at any time during this period Prior treatment with more than lines of therapy (combination treatments are considered line of therapy) Patients with R/R PTCL who have received at least one and no more than three previous lines of therapy are eligible to be enrolled in this study At least one and up to two previous lines of systemic cytotoxic therapy for advanced NSCLC, of which one must have been a platinum-based doublet therapy. Up to four total previous lines of systemic therapy (including immunotherapy and molecularly targeted therapy) Relapsed disease after at least lines of therapy Receipt of >/= but not more than prior lines of therapy (Cohorts A, B, C, D, E) Receipt of >/= lines of prior therapy and are refractory to the last line of treatment (Cohort F) Previously untreated or treated subjects with no limit on prior lines of systemic therapies are allowed Patients with steroid refractory cGVHD typically have received salvage with multiple lines of therapy; hence in this trial there will be no restriction in terms of prior lines of therapy received; prior ECP exposure is allowed, however prior IL- use is excluded Received less than lines of anti-myeloma therapy All lines of prior therapy accepted; subjects with prior hepatic or extra-hepatic resections of metastatic disease will be included Patients can have any lines (including zero) of prior therapy to sign consent prior to tissue harvest; vaccination will not take place until at least one line of standard chemotherapy is given Patients who have received up to two previous lines of systemic chemotherapy are eligible for this trial Subjects must have had at least three lines of therapy for their disease, including a proteasome inhibitor and immunomodulatory drug (e.g., lenalidomide), with lines of therapy being separated by the presence of documented disease progression; using this definition, treatment with induction therapy, followed by high dose chemotherapy and autologous stem cell transplantation, and finally by maintenance therapy, would constitute one line, provided that multiple myeloma did not meet criteria for progression at any time during this period Must have undergone prior treatment with ? treatment lines of anti-myeloma therapy and failed last line of treatment (disease progression ? days of completion of last therapy) At least one but no more than three prior lines of therapy in the advanced stage are allowed. One prior line of therapy must be platinum doublet chemotherapy. More than three lines of prior therapy. More than lines of therapy beyond corticosteroids with or without calcineurin inhibitors or sirolimus There will be no limits to prior lines of treatment Prior systemic therapy: (a) Phase b: Any number of lines of prior therapy; (b) Phase : Progressed after or lines of prior chemotherapy Received no more than prior lines of systemic therapy for metastatic disease. Patients must have received at least prior lines of therapy (Note: Induction therapy and stem cell transplant maintenance will be considered as one line). Criteria Received at least but not more than prior lines of therapy for multiple myeloma (induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as line of therapy, see Appendix E for guidance) No more than prior lines of anti leukemia therapy (not including ibrutinib) No more than prior lines of anti leukemia therapy (not including ibrutinib) Refractory to and disease progression within months from the last dose of at least lines of prior therapy Has received at least prior lines of therapy as described in the protocol. For Part , prior treatment with less than prior lines of chemotherapy No limits to the prior lines of treatment Progression on at least two prior lines of therapy for unresectable metastatic colorectal adenocarcinoma\r\n* Administration of bevacizumab previously does not impact study inclusion RENAL COHORT: Any number of prior treatment lines is allowed on study Patients can have any lines (including zero) of prior therapy to sign consent prior to tissue harvest Any number of prior lines of therapy Subjects with one to three lines of therapy for their disease with lines of therapy being separated by the presence of documented disease progression; using this definition, treatment with induction therapy, followed by high dose chemotherapy and autologous stem cell transplantation, and finally by maintenance therapy, would constitute one line, provided that multiple myeloma did not meet criteria for progression at any time during this period Patient must have received or more prior lines of systemic therapy for myeloma; patients must be off last treatment for at least weeks (wks) by the beginning of treatment on this protocol Subjects may have received no more than lines of prior therapy for advanced disease. Subjects may have received no more than lines of prior therapy for advanced disease. Subjects may have received no more than lines of prior therapy for the advanced disease previously received at least but no more than lines of therapy, one therapy must have included a VEGF TKI previously received at least but no more than lines of therapy, one therapy must have included a fluoropyrimidine based regimen Histologically confirmed metastatic soft tissue sarcoma (i.e., non-GIST, non-adipocytic) that has progressed by RECIST following treatment with anthracycline chemotherapy. Patients may have received up to four lines of systemic therapy for metastatic disease and no more than two lines of combination treatment ( Phase only) Received prior treatment with at least , but no more than , prior lines of therapy for MM. Three or more prior lines of systemic therapy for GBM. There is no limitation in the number of prior lines of therapy Had more than prior lines of systemic therapy. Maintenance therapies and hormonal therapies are not considered additional lines of therapy Must have undergone prior treatment with ? treatment lines of anti-myeloma therapy Has histopathologically confirmed nonsquamous or squamous NSCLC with documented disease progression after - prior lines of systemic therapy Has histologically confirmed biliary tract adenocarcinoma with documented progression after - prior lines of systemic therapy Has received ? lines of prior systemic therapy for gastric or GEJ adenocarcinoma and BTC or ? lines for NSCLC or urothelial cancer. Patient has had at least or more prior lines of therapy including lenalidomide and bortezomib and has demonstrated disease progression on or within days of completion of the last therapy Participant must have received prior treatment with at least one, but no more than three, prior lines of therapy for multiple myeloma. A line of therapy consists of greater than or equal to complete cycle of a single agent, a regimen consisting of combination of several drugs, or a planned sequential therapy of various regimens. must have received at least but no greater than prior lines of therapy (note: induction and stem cell transplants with or without maintenance therapy is considered line of therapy) MEL subjects may be treatment nave or may have received prior lines of therapy for metastatic disease (Parts A and B) The patient must have received no more than prior lines of therapy for metastatic disease. The patient must have received no more than prior lines of therapy for metastatic disease. At least three prior lines of therapy for advanced ovarian cancer as defined in the protocol Treatment naive patients in first-line or pre-treated patients with no more than lines of prior therapy Patients in Phase expansion cohort B will have experienced disease progression with or prior lines of therapy, including up to prior line of liver-directed therapy Received or prior lines of therapy. More than three prior lines of cytotoxic therapy. Has histopathologically confirmed nonsquamous or squamous NSCLC with documented disease progression after - prior lines of systemic therapy No more than two prior lines of chemotherapy for metastatic sarcoma are allowed; neoadjuvant/adjuvant chemotherapy with definitive therapy (radiation, surgery or radiation and surgery) will not be counted as one of these prior lines of therapy; non-cytotoxic therapies will not be counted as one of these prior lines of therapy Pancreatic neuroendocrine patients must have had progression after prior therapy; patients with other foregut neuroendocrine tumors must have had progressive disease over the last months, irrespective of prior therapy; patients with both functional (who may continue somatostatin analogues as required for control of related symptoms) and non-functional tumors are eligible; in patients who have previously received therapy, the number of prior lines of therapy should not be more than lines of systemic therapy not including somatostatin analogues Subject that have received more than prior lines of chemotherapy must not have liver metastases Patients must have received two or more prior lines of treatment. A previous regimen is defined as one of the following: at least two months of single-agent therapy, at least two consecutive cycles of polychemotherapy, autologous transplant, radioimmunotherapy. Patients must have previously treated relapsed and/or refractory MCL with at least prior lines of therapy (prior carfilzomib, ibrutinib, bortezomib, anthracycline, rituximab or stem cell transplant are acceptable); there is no upper limit for prior lines of therapy Patients must have received at least two prior lines of therapy and also must be refractory to lenalidomide (defined as progression while on active therapy or within days of discontinuation); one prior line of therapy may consist of all predetermined components of induction followed by autologous stem cell transplantation and maintenance Patients may have received unlimited lines of prior therapy At least and no more than prior lines of therapy for incurable or metastatic NSCLC Received more than lines of prior conventional therapy for advanced disease No more than prior lines of systemic anti-cancer therapy. Male and female, ages and above, with relapsed or refractory FL lymphoma after > or = prior treatment lines; each of the prior treatment lines must include at least CD antibody and/or an alkylating agent Symptomatic myeloma that has progressed/relapsed after to prior lines of therapy One or more prior lines of cytotoxic treatment for advanced disease (prior hormonal therapy is not considered to count as prior lines of therapy) The patient has received =< lines of prior therapy PART B: Patients must have received prior platinum-based chemotherapy but may have received any number of other lines of prior therapy More than prior lines of chemotherapy for recurrent cancer. Secretory MM for which the patient previously received - prior lines of therapy (Phase ). - prior lines of therapy May have received up to two prior lines of chemotherapy for advanced disease More than prior lines of CLL therapy. All patients may have received up to two prior lines of chemotherapy for recurrent/advanced disease Patients must have received at least one but no more than prior lines of systemic therapy For participation in the Phase I portion, patients must have completed either one or two lines of prior therapy No more than prior lines of systemic anti-cancer therapy. Subjects who progressed after receiving at least , but no more than , prior SoC treatment lines For Phase b of the study: Participants who have experienced failure of multiple lines of prior chemotherapy are eligible. Eligible subjects are required to have > or = to line of multi-agent chemotherapy either neoadjuvantly or adjuvantly. Subjects may have had - lines of therapy for metastatic disease. Previously received at least , but no more than , lines of therapy including at least course of platinum-based therapy More than three prior lines of chemotherapy Must have received or prior lines of conventional molecularly targeted therapy Received at least prior lines of therapy (induction therapy and stem cell transplant maintenance are to be considered a single line of therapy). No more than prior lines of therapy Patients must have received >= previous lines of therapy that must have included bortezomib and Revlimid; patients must have received , but no more than prior treatment regimens or lines of therapy for multiple myeloma; (induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as one line of therapy) For Part , subject has received or more prior lines of cytotoxic chemotherapy for systemic disease. Received , but no more than prior treatment regimens or lines of therapy for multiple myeloma. (Induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as one line of therapy). Subjects must have undergone prior treatment with ? treatment lines of anti-myeloma therapy